Hubungan Rasio Trombosit Limfosit Dengan Penyempitan Pembuluh Darah Pada Penyakit Jantung Koroner
DAFTAR PUSTAKA
1. James K.Min, MD. Coronary CTA versus cardiac catheterization: Where
do We stand today? Well Medical College of Cornell University. New
York- Presbyterian Hospital, New York, NY.2006
2. Libby P, Bonow RO, Mann DL.Braunwald’s heart disease: A textbook of
Cardiovascular medicine. 8th ed. 2007
3. Alwi Idrus. Hanafi Muin Rahman, S Harun. Ilmu Penyakit Dalam jilid
III. Penyadapan Jantung ( Cardiac Catheterization) Jakarta: FKUI 2006,
hal 1491-496
4. Departemen Kesehatan RI, 2012, Penyakit Tidak Menular. In : Buletin
Jendela dan Data Kesehatan ISSN 2088-207X.Jakarta: Bakti Husada
5. Karol Watson,MD,PhD, 2001.CHD Based upon the more stringent
guidelines Of ATP III,as compared to ATP II, a more aggressive
treatment strategy is warranted in dyslipidemia patient, Advanced
Studies in Medicine, JA MA ;285:2486-2497
6. Gary T, Pichler M, Belaj K.et. al. 2013. Platelet-to-lymphocyte ratio: a
novel marker for critical limb ischemia in peripheral arterial occlusive
disease patients. PloS One; 8: e67688.
7. Smith RA, Ghaneh P, Sutton R, et.al. 2008. Prognosis of resected
ampullary Adenocarcinoma by preoperative serum CA19- 9 levels and
platelet- lymphocyte ratio. J Gastrointest Surg; 12: 1422-8.
8.
Göran K. Hansson, M.D., Ph.D. 2005. N Engl J Med;352:1685.95
Guidelines for the management of the patiens with chronic stable
stable angina. Circulation. 2007; 116:2762-2772
Universitas Sumatera Utara
9. Alwi Idrus, Setiati S, Sudoyo Aru W. et.al. 2014. Ilmu Penyakit
Dalam.Jakarta : Internal Publishing : 1292-1293
10. McKay J, George AM, Shantu M. et.al. The atlas of heart disease and
stroke. World Health Organization. Geneva; 2004
11. Acanfora D, Gheorghiade M, Trojano L. C, et al. 2001. Relative
lymphocyte count: a prognostic indicator of mortality in erderly
patients with congestive heart failure. Am Heart J; 142 : 167-73
12. Nikolsky E. Grines CL, Cox DA. Impact of Baseline platelet count in
patients undergoing primary percutaneous coronary interventionin
acute myocardial infarction (from the CADILLAC trial). Am J Cardiol ;
2007;99: 1055-61
13. Zouridakis EG, Garcia-Moll X, Kaski JC. Et.al.2000. Usefulness of the
blood lymphocyte count in predicting recurrent instability and death in
patients with unstable angina pectoris. Am J Cardiol; 86: 449-51
14. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. 1991.
Blood platelet count and function are related to total and
cardiovascular death in apparently healthy men. Circulation; 84: 6137
15. Proctor MJ, Morrison DS, Talwar D. et al. 2011. A comparison of
inflammation-based prognostic scores in patients with cancer. A
Glasgow Inflammation Outcome Study. Eur J Cancer; 47: 2633-41
16. Azab B, Shah N, Akerman M. 2012. Value of platelet / lymphocyte
ratio as a predictor of all-cause mortality after non-STelevation
myocardial infarction. J Thromb Thrombolysis; 34:326-34
Universitas Sumatera Utara
17. Yıldız A, Yuksel M, Oylumlu M. et al. 2014 .The Utility of The
platelet-lymphocyte ratio for predicting no reflow in patients with STsegment elevation myocardial infarction. Clin Appl Thromb Hemost
18. Yüksel M, Yıldız A, Oylumlu Mustafa. Patelet/lymphocyte ratio and
CAD,Department of Cardiology, Faculty of Medicine, Dicle University;
Diyarbakır-Turkey ; Anadolu Kardiyol Derg; 2014.;14(0)
19. Rilanto L.I, Tedjokusumo. P. Patogesis Arterosklerosis. 5 Rahasia
Untuk Menanggulangi Penyakit Kardiovaskular. FKUI. 2012; 127-131
20. ACC/AHA Guideline on the Assessment of Cardiovascular Risk, 2013
http://dx.doi.org/10.1161/01.cir.00000437741.48606.98
21. Falk E, Shah PK, Fuster V. Coronary Plaque Distruption. Circulation
2005; 92:657-671
22. Han YC, Yang TH, Kim DI, Jin HY, Chung SR, Seo JS, et al. 2013.
Neutrophil to Lymphocyte Ratio Predicts Long-Term Clinical
Outcomes in patients with ST-Segment Elevation Myocardial
Infarction
Undergoing
Primary
Percutaneous
Coronary
Intervention.Korean Circ J; 43: 93-9.
23. Beltrame John F., Rachel Dreyer, Rosanna Tavella.et.al. 2001.
Discipline of Medicine, University of Adelaide. Circulation 104: 274653.
24. Kozak M. Robertson BJ.
Chambers CE. Cardiac catheterization
laboratory: Diagnostic and Therapeutic Procedures in the Adult Patient.
Kaplans
Cardiac
Anesthesia.
Saunders
Elsevier.
5Ed.
Philadelphia.2006; 12:299-354
Universitas Sumatera Utara
25. Kumar V MD. Cotran R MD. Robin ZL MD. Basic patology. MB
Saunders Co. Philadelphia. 1997. 282-92
26. Constaninides. P. The Commonest Causes of Anoxic Necrosis. Dalam:
General Pathobiology Norwalk Connecticut: Appleton & Lange. 1999;
59-16
27. Ross Russel. Atherosclerosis an Inflamatory Disease. Available from:
Http://content.nejm.org/cgi/content/full/340/2/115/. 1999
28. Shimokawa. H. Clinical Assessment of Endothelial Function.
Available from: http://www.j.circ.or.jp/englishsessions/repost/64th55/shimikawa.htm. 2000
29. Tuveri M. Pathophysiological Aspects of Vascular Disease. Role
Hemodynamic Factor. Biomedical Application Group. METDST 1999.
September 2; 18:51:14
30. Stary HC, Chandler AB, Dinsmore RE. A definition of advanced types
of atherosclerotic lesions and a histological classification of
atherosclerosis: a report from the Committee on Vascular Lesions of
the Council on Arteriosclerosis, American Heart Association.
Circulation; 1995; 92:1355-74.
31. Pepine CJ. Rupture Adapted. Am J Cardiol. 1998; 82(suppl 104)
32. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420:868–874.
33. Libby P, Lee RT. Matrix matters. Circulation. 2000;102:1874 –1876
34. Williams KJ, Tabas I. The response-to-retention hypothesis of
atherogenesis reinforced. Curr Opin Lipidol. 1998;9:471– 474)
Universitas Sumatera Utara
35. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D.
Evidence for a role of phospholipid oxidation products in
atherogenesis.Trends Cardiovasc Med. 2001;11:142–147
36. Demer LL. Vascular calcification and osteoporosis: inflammatory
responses to oxidized lipids. Int J Epidemiol. 2002;31:737–741
37. Geng YJ, Libby P. Progression of atheroma: a struggle between death
and procreation. Arterioscler Thromb Vasc Biol. 2002; 22: 1370 –1380
38. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M,
Nemerson Y. Alternatively spliced human tissue factor: a circulating,
soluble, thrombogenic protein. Nat Med. 2003; 9:458–462.
39. Libby P, Ridker PM, Maseri an Inflammation and Atherosclerosis.
Circulation 2005; 102:135-432 2.3.4.5.6.7.8.9.10.2011.
40. Frakter TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J. et
al. 2002. Chronic angina focused update of the ACC/AHA 2002.
Guidelines for the management of patients with chronic stable angina:
a report of American College of Cardiology/American Heart
Association task Force on Practice Guidelines Writing Group to
develop focused of the 2002
41. Lock JE, Rome JJ, Davis R, et al. Transcatheter closure of atrial septal
d efects. Experimental studies. Circulation 1989;79: 1091 1099
42. Sultan D. Sheriff, Sachu P. and Elshaari F.A. HDL, apo B / apo A1
ratio,
Diabetes
Mellitus
and
Cardiovascular
Disease.Intech.Chap.8;2013 http : //dx.doi.org/10.5772/56476
Universitas Sumatera Utara
43. Arthur Selter, MD, William L. Anderson, MD, Harold W. March, MD.
2001. Indication for Coronary Arteriography Risks Vs Benefits.
California Medicine. The Western Journal of Medicine. 2001
44. Guidelines for the management of the patiens with chronic stable
stable angina. Circulation. 2007; 116:2762-2772
45. Hoffbrand, A.V., J.E, Pettit, P.A.H, Moss, 2005. Kapita Selekta
Hematologi, Jakarta: ECG.
46. Massberg, S., et al. A crucial role of glycoprotein VI for platelet
recruitment to the injured arterial wall in vivo. J. Exp. Med. 2003;
197:41–49.
47. Balduini CL, Noris P. 2014. Platelet count and aging. Haematologica.
2014 Jun; 99(6):953-5.doi: 10.3324/haematol.2014.106260.
48. Kickler TS. Clinical analyzers: advances in automated cell counting.
Anal Chem 1999; 71:363-5.
49. Madjid M, Fatemi O. Component of the complete blood count as risk
Predictor for coronary heart disease. Text Heart Inst J 2013; 40 (1):1729
50. Hilman Robert S, Ault Kenneth A, Rinder Henry M., hematology in
clinical practice: a guide to diagnosis and management. Lange ,Mc
Graw Hill, 2005 ;19;235-247
51. Karnen Baratawijaya, Immunologi Dasar. Didalam Soepannan
Sarwono Waspadji, Ilmu Penyakit Dalam, edisi 2. Jakarta: Gaya Baru
1996
Universitas Sumatera Utara
52. Frostegård J, Ulfgren AK, Nyberg P, et al. 1999.Cytokine expressio in
Advanced
human
atherosclerotic
plaques:
dominance
proinflammatory (Th1) and macrophage- stimulating
of
cytokines.
Atherosclerosis; 145: 33-43
53. Lutters B. C. H, Ronald H. W. M. Derksen. et. al. 2003. Dimers of 2Glycoprotein I Increase Platelet Deposition to Collagen via
Interaction with Phospholipids and the Apolipoprotein E Receptor 2.
The Journal of Biological Chemistry. The American Society For
Biochemistry and Molecular, Inc. Vol. 278, pp. 33831-33838
54. Body R, Carley S, McDowell G. et.al 2011. Rapid exclusion of acute
myocardial infarction in patients with undetectable troponin using a
high sensitivity assay. J Am Coll Cardiol; 58: 1333-9.
55. Ommen SR, Hodge DO, Rodeheffer RJ, McGregor CG, Thomson SP,
Gibbons RJ. Predictive power of the relative lymphocyte concentration
in patients with advanced heart failure. Circulation 1998; 97: 19-22
56. Dragu R, Khoury S, Zuckerman R, Suleiman M, Mutlak D, Agmon
Y,et al. Predictive value of white blood cell subtypes for long-term
outcome following myocardial infarction. Atherosclerosis 2008;
196(1):405-12.
57. Tabas I. Nonoxidative modifications of lipoproteins in atherogenesis.
Ann Rev Nutr. 1999; 19: 123–139.
58. Meade TW, Cooper JA,Miller GJ, platelet counts ang aggregation
measure In the Incidence of ischaemic heart disease (IHD). Thromb
haemost 1997; 78 (2):926-9
Universitas Sumatera Utara
59. Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Katdare
AD, Inamdar AK. Platelet volume indices in patients with coronary
artery disease and acute myocardial infarction: an Indian scena. J Clin
Pathol. 2006; 59(2):146–149. [PMC free article] [PubMed]
60. Dahlan S. Langkah-langkah Membuat Proposal Penelitian Bidang
Kedokteran dan Kesehatan. Sagung Seto. Seri 3 Edisi 2
Universitas Sumatera Utara
1. James K.Min, MD. Coronary CTA versus cardiac catheterization: Where
do We stand today? Well Medical College of Cornell University. New
York- Presbyterian Hospital, New York, NY.2006
2. Libby P, Bonow RO, Mann DL.Braunwald’s heart disease: A textbook of
Cardiovascular medicine. 8th ed. 2007
3. Alwi Idrus. Hanafi Muin Rahman, S Harun. Ilmu Penyakit Dalam jilid
III. Penyadapan Jantung ( Cardiac Catheterization) Jakarta: FKUI 2006,
hal 1491-496
4. Departemen Kesehatan RI, 2012, Penyakit Tidak Menular. In : Buletin
Jendela dan Data Kesehatan ISSN 2088-207X.Jakarta: Bakti Husada
5. Karol Watson,MD,PhD, 2001.CHD Based upon the more stringent
guidelines Of ATP III,as compared to ATP II, a more aggressive
treatment strategy is warranted in dyslipidemia patient, Advanced
Studies in Medicine, JA MA ;285:2486-2497
6. Gary T, Pichler M, Belaj K.et. al. 2013. Platelet-to-lymphocyte ratio: a
novel marker for critical limb ischemia in peripheral arterial occlusive
disease patients. PloS One; 8: e67688.
7. Smith RA, Ghaneh P, Sutton R, et.al. 2008. Prognosis of resected
ampullary Adenocarcinoma by preoperative serum CA19- 9 levels and
platelet- lymphocyte ratio. J Gastrointest Surg; 12: 1422-8.
8.
Göran K. Hansson, M.D., Ph.D. 2005. N Engl J Med;352:1685.95
Guidelines for the management of the patiens with chronic stable
stable angina. Circulation. 2007; 116:2762-2772
Universitas Sumatera Utara
9. Alwi Idrus, Setiati S, Sudoyo Aru W. et.al. 2014. Ilmu Penyakit
Dalam.Jakarta : Internal Publishing : 1292-1293
10. McKay J, George AM, Shantu M. et.al. The atlas of heart disease and
stroke. World Health Organization. Geneva; 2004
11. Acanfora D, Gheorghiade M, Trojano L. C, et al. 2001. Relative
lymphocyte count: a prognostic indicator of mortality in erderly
patients with congestive heart failure. Am Heart J; 142 : 167-73
12. Nikolsky E. Grines CL, Cox DA. Impact of Baseline platelet count in
patients undergoing primary percutaneous coronary interventionin
acute myocardial infarction (from the CADILLAC trial). Am J Cardiol ;
2007;99: 1055-61
13. Zouridakis EG, Garcia-Moll X, Kaski JC. Et.al.2000. Usefulness of the
blood lymphocyte count in predicting recurrent instability and death in
patients with unstable angina pectoris. Am J Cardiol; 86: 449-51
14. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. 1991.
Blood platelet count and function are related to total and
cardiovascular death in apparently healthy men. Circulation; 84: 6137
15. Proctor MJ, Morrison DS, Talwar D. et al. 2011. A comparison of
inflammation-based prognostic scores in patients with cancer. A
Glasgow Inflammation Outcome Study. Eur J Cancer; 47: 2633-41
16. Azab B, Shah N, Akerman M. 2012. Value of platelet / lymphocyte
ratio as a predictor of all-cause mortality after non-STelevation
myocardial infarction. J Thromb Thrombolysis; 34:326-34
Universitas Sumatera Utara
17. Yıldız A, Yuksel M, Oylumlu M. et al. 2014 .The Utility of The
platelet-lymphocyte ratio for predicting no reflow in patients with STsegment elevation myocardial infarction. Clin Appl Thromb Hemost
18. Yüksel M, Yıldız A, Oylumlu Mustafa. Patelet/lymphocyte ratio and
CAD,Department of Cardiology, Faculty of Medicine, Dicle University;
Diyarbakır-Turkey ; Anadolu Kardiyol Derg; 2014.;14(0)
19. Rilanto L.I, Tedjokusumo. P. Patogesis Arterosklerosis. 5 Rahasia
Untuk Menanggulangi Penyakit Kardiovaskular. FKUI. 2012; 127-131
20. ACC/AHA Guideline on the Assessment of Cardiovascular Risk, 2013
http://dx.doi.org/10.1161/01.cir.00000437741.48606.98
21. Falk E, Shah PK, Fuster V. Coronary Plaque Distruption. Circulation
2005; 92:657-671
22. Han YC, Yang TH, Kim DI, Jin HY, Chung SR, Seo JS, et al. 2013.
Neutrophil to Lymphocyte Ratio Predicts Long-Term Clinical
Outcomes in patients with ST-Segment Elevation Myocardial
Infarction
Undergoing
Primary
Percutaneous
Coronary
Intervention.Korean Circ J; 43: 93-9.
23. Beltrame John F., Rachel Dreyer, Rosanna Tavella.et.al. 2001.
Discipline of Medicine, University of Adelaide. Circulation 104: 274653.
24. Kozak M. Robertson BJ.
Chambers CE. Cardiac catheterization
laboratory: Diagnostic and Therapeutic Procedures in the Adult Patient.
Kaplans
Cardiac
Anesthesia.
Saunders
Elsevier.
5Ed.
Philadelphia.2006; 12:299-354
Universitas Sumatera Utara
25. Kumar V MD. Cotran R MD. Robin ZL MD. Basic patology. MB
Saunders Co. Philadelphia. 1997. 282-92
26. Constaninides. P. The Commonest Causes of Anoxic Necrosis. Dalam:
General Pathobiology Norwalk Connecticut: Appleton & Lange. 1999;
59-16
27. Ross Russel. Atherosclerosis an Inflamatory Disease. Available from:
Http://content.nejm.org/cgi/content/full/340/2/115/. 1999
28. Shimokawa. H. Clinical Assessment of Endothelial Function.
Available from: http://www.j.circ.or.jp/englishsessions/repost/64th55/shimikawa.htm. 2000
29. Tuveri M. Pathophysiological Aspects of Vascular Disease. Role
Hemodynamic Factor. Biomedical Application Group. METDST 1999.
September 2; 18:51:14
30. Stary HC, Chandler AB, Dinsmore RE. A definition of advanced types
of atherosclerotic lesions and a histological classification of
atherosclerosis: a report from the Committee on Vascular Lesions of
the Council on Arteriosclerosis, American Heart Association.
Circulation; 1995; 92:1355-74.
31. Pepine CJ. Rupture Adapted. Am J Cardiol. 1998; 82(suppl 104)
32. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420:868–874.
33. Libby P, Lee RT. Matrix matters. Circulation. 2000;102:1874 –1876
34. Williams KJ, Tabas I. The response-to-retention hypothesis of
atherogenesis reinforced. Curr Opin Lipidol. 1998;9:471– 474)
Universitas Sumatera Utara
35. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D.
Evidence for a role of phospholipid oxidation products in
atherogenesis.Trends Cardiovasc Med. 2001;11:142–147
36. Demer LL. Vascular calcification and osteoporosis: inflammatory
responses to oxidized lipids. Int J Epidemiol. 2002;31:737–741
37. Geng YJ, Libby P. Progression of atheroma: a struggle between death
and procreation. Arterioscler Thromb Vasc Biol. 2002; 22: 1370 –1380
38. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M,
Nemerson Y. Alternatively spliced human tissue factor: a circulating,
soluble, thrombogenic protein. Nat Med. 2003; 9:458–462.
39. Libby P, Ridker PM, Maseri an Inflammation and Atherosclerosis.
Circulation 2005; 102:135-432 2.3.4.5.6.7.8.9.10.2011.
40. Frakter TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J. et
al. 2002. Chronic angina focused update of the ACC/AHA 2002.
Guidelines for the management of patients with chronic stable angina:
a report of American College of Cardiology/American Heart
Association task Force on Practice Guidelines Writing Group to
develop focused of the 2002
41. Lock JE, Rome JJ, Davis R, et al. Transcatheter closure of atrial septal
d efects. Experimental studies. Circulation 1989;79: 1091 1099
42. Sultan D. Sheriff, Sachu P. and Elshaari F.A. HDL, apo B / apo A1
ratio,
Diabetes
Mellitus
and
Cardiovascular
Disease.Intech.Chap.8;2013 http : //dx.doi.org/10.5772/56476
Universitas Sumatera Utara
43. Arthur Selter, MD, William L. Anderson, MD, Harold W. March, MD.
2001. Indication for Coronary Arteriography Risks Vs Benefits.
California Medicine. The Western Journal of Medicine. 2001
44. Guidelines for the management of the patiens with chronic stable
stable angina. Circulation. 2007; 116:2762-2772
45. Hoffbrand, A.V., J.E, Pettit, P.A.H, Moss, 2005. Kapita Selekta
Hematologi, Jakarta: ECG.
46. Massberg, S., et al. A crucial role of glycoprotein VI for platelet
recruitment to the injured arterial wall in vivo. J. Exp. Med. 2003;
197:41–49.
47. Balduini CL, Noris P. 2014. Platelet count and aging. Haematologica.
2014 Jun; 99(6):953-5.doi: 10.3324/haematol.2014.106260.
48. Kickler TS. Clinical analyzers: advances in automated cell counting.
Anal Chem 1999; 71:363-5.
49. Madjid M, Fatemi O. Component of the complete blood count as risk
Predictor for coronary heart disease. Text Heart Inst J 2013; 40 (1):1729
50. Hilman Robert S, Ault Kenneth A, Rinder Henry M., hematology in
clinical practice: a guide to diagnosis and management. Lange ,Mc
Graw Hill, 2005 ;19;235-247
51. Karnen Baratawijaya, Immunologi Dasar. Didalam Soepannan
Sarwono Waspadji, Ilmu Penyakit Dalam, edisi 2. Jakarta: Gaya Baru
1996
Universitas Sumatera Utara
52. Frostegård J, Ulfgren AK, Nyberg P, et al. 1999.Cytokine expressio in
Advanced
human
atherosclerotic
plaques:
dominance
proinflammatory (Th1) and macrophage- stimulating
of
cytokines.
Atherosclerosis; 145: 33-43
53. Lutters B. C. H, Ronald H. W. M. Derksen. et. al. 2003. Dimers of 2Glycoprotein I Increase Platelet Deposition to Collagen via
Interaction with Phospholipids and the Apolipoprotein E Receptor 2.
The Journal of Biological Chemistry. The American Society For
Biochemistry and Molecular, Inc. Vol. 278, pp. 33831-33838
54. Body R, Carley S, McDowell G. et.al 2011. Rapid exclusion of acute
myocardial infarction in patients with undetectable troponin using a
high sensitivity assay. J Am Coll Cardiol; 58: 1333-9.
55. Ommen SR, Hodge DO, Rodeheffer RJ, McGregor CG, Thomson SP,
Gibbons RJ. Predictive power of the relative lymphocyte concentration
in patients with advanced heart failure. Circulation 1998; 97: 19-22
56. Dragu R, Khoury S, Zuckerman R, Suleiman M, Mutlak D, Agmon
Y,et al. Predictive value of white blood cell subtypes for long-term
outcome following myocardial infarction. Atherosclerosis 2008;
196(1):405-12.
57. Tabas I. Nonoxidative modifications of lipoproteins in atherogenesis.
Ann Rev Nutr. 1999; 19: 123–139.
58. Meade TW, Cooper JA,Miller GJ, platelet counts ang aggregation
measure In the Incidence of ischaemic heart disease (IHD). Thromb
haemost 1997; 78 (2):926-9
Universitas Sumatera Utara
59. Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Katdare
AD, Inamdar AK. Platelet volume indices in patients with coronary
artery disease and acute myocardial infarction: an Indian scena. J Clin
Pathol. 2006; 59(2):146–149. [PMC free article] [PubMed]
60. Dahlan S. Langkah-langkah Membuat Proposal Penelitian Bidang
Kedokteran dan Kesehatan. Sagung Seto. Seri 3 Edisi 2
Universitas Sumatera Utara